CXCL9 and neoplasm: Of interest, type I IFNs can reverse the T cell suppressive activity of multiple tumor-associated myeloid cells, including macrophages, neutrophils, monocytes, and DCs by enhancing expression of T cell co-stimulatory molecules, IL-12 production, the ability to process and cross-present tumor antigens, and secretion of T cell attractive chemokines such as CXCL9/10 (16, 21).